Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenHibrix (HibMenCY-TT) is a trivalent conjugate vaccine developed by GlaxoSmithKline (GSK) to protect infants and children against invasive diseases caused by *Haemophilus influenzae* type b (Hib) and *Neisseria meningitidis* serogroups C and Y. The vaccine consists of the capsular polysaccharides of these three bacterial pathogens, each individually and covalently linked to a tetanus toxoid carrier protein. This conjugation process converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which is essential for inducing a robust immune response and immunological memory in young children. MenHibrix was approved by the FDA in 2012 for use in infants aged 6 weeks through 18 months. However, GSK discontinued the product in the United States in 2016 due to low market demand rather than safety or efficacy concerns.
- Brand names
- MenHibrix
- Other names
- Hib-MenCY-TTHaemophilus b and Meningococcal (Groups C and Y) Tetanus Toxoid Conjugate Vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine.